Previously, the task force only recommended Truvada and its generics for use as pre-exposure prophylaxis to prevent HIV. Now, the expert panel is also backing the pill Descovy and the injectable medication Apretude as additional options.
The recommendation means private insurers will be required to cover the drugs without co-pays or deductibles and comes as the White House aims to preserve coverage of preventive services under the ACA, according to The New York Times. Last year, a federal judge ruled the mandate unconstitutional, arguing that requiring private insurers to cover PREP, in particular, violated employers’ religious rights.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
